The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity-Reference-Cited by-同舟云学术

The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity

Published:2023-11-07 Issue:12 Volume:20 Page:1445-1456
ISSN:2042-0226
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Yu Jizhang,Cui Jikai,Zhang Xi,Xu Heng,Chen Zhang,Li Yuan,Niu Yuqing,Wang Song,Ran Shuan,Zou Yanqiang,Ye Weicong,Zhang Dan,Zhou Cheng,Xia Jiahong,Wu Jie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41423-023-01093-y.pdf

Reference63 articles.

1. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002–14.

2. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–63.

3. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.

4. O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–27.

5. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162:5813–20.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets;Experimental Hematology & Oncology;2024-08-30

2. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

3. PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration;Cell Death & Disease;2024-07-23

4. TRAF6 promotes spinal microglial M1 polarization to aggravate neuropathic pain by activating the c-JUN/NF-kB signaling pathway;Cell Biology and Toxicology;2024-07-12

5. PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration;2024-05-14